Literature DB >> 11458815

Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.

K Boumédiene1, M Takigawa, J P Pujol.   

Abstract

In this study, the growth properties of the human chondrosarcoma cell line HCS-2/8, its response to transforming growth factor (TGF)-beta isoforms 1, 2, and 3, and its expression of TGF-beta receptors I and II were examined. We demonstrated that these tumor cells are not contact-inhibited and that they can proliferate in the absence of additional serum growth factors. In sparse cultures, all TGF-beta forms inhibited the growth of HCS-2/8 cells, whereas they induced a 2-fold increase of DNA synthesis in serum-fed confluent cultures. In serum-free confluent conditions only TGF-beta 1 stimulated the proliferation rate, whereas TGF-beta 2 was without effect and TGF-beta 3 was rather inhibitory. This bimodal effect of TGF-beta forms was associated with a greater level of TGF-beta receptor 1 mRNA in confluent HCS-2/8 than in sparse cultures, suggesting that the growth response to TGF-beta forms is dependent on the receptor profile expressed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458815     DOI: 10.1081/cnv-100103846

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

1.  Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.

Authors:  Julia Dambacher; Florian Beigel; Julia Seiderer; Dirk Haller; Burkhard Göke; Christoph J Auernhammer; Stephan Brand
Journal:  Gut       Date:  2007-04-20       Impact factor: 23.059

2.  Lumican mediates HTB94 chondrosarcoma cell growth via an IGF‑IR/Erk1/2 axis.

Authors:  Antonis Papoutsidakis; Eirini Maria Giatagana; Aikaterini Berdiaki; Ioanna Spyridaki; Demetrios A Spandidos; Aristidis Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Int J Oncol       Date:  2020-07-06       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.